Gilead Sciences Ltd commissioned PHAST to undertake some research to inform the next steps in NASH and NAFLD Service Delivery. Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, they seek to improve the care of patients living with life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, haematology and oncology, inflammatory and respiratory diseases and cardiovascular conditions.
Phase 1: Desktop exercise of evidence synthesis and data analysis
Phase 2: Stakeholder mapping, engagement and consultation
Phase 3: Recommendations for supporting the future development of NAFLD/NASH care pathways
You can download the presentation below